Zobrazeno 1 - 10
of 63
pro vyhledávání: '"Ulla Wartiovaara- Kautto"'
Autor:
Atte K Lahtinen, Jessica Koski, Jarmo Ritari, Kati Hyvärinen, Satu Koskela, Jukka Partanen, Kim Vettenranta, Minna Koskenvuo, Riitta Niittyvuopio, Urpu Salmenniemi, Maija Itälä-Remes, Kirsi Jahnukainen, Outi Kilpivaara, Ulla Wartiovaara- Kautto, Maarja Karu
Publikováno v:
EJC Paediatric Oncology, Vol 2, Iss , Pp 100058- (2023)
Externí odkaz:
https://doaj.org/article/00460f5941584e5d97b84798c1738c14
Autor:
Marja Hakkarainen, Jessica R. Koski, Caroline A. Heckman, Pekka Anttila, Raija Silvennoinen, Juha Lievonen, Outi Kilpivaara, Ulla Wartiovaara‐Kautto
Publikováno v:
eJHaem, Vol 3, Iss 4, Pp 1352-1357 (2022)
Abstract Observations of inherited susceptibility to multiple myeloma have led to active research in defining predisposing genes to the disease. Here, we analysed 128 plasma cell dyscrasia patients’ germline whole‐exome sequencing data. Rare domi
Externí odkaz:
https://doaj.org/article/2c12cac227bf47e280d6d74f3b53ad94
Autor:
Laura Langohr, Ilse Kaaja, Suvi Douglas, Tuulia Räisänen, Sadiksha Adhikari, Markus Vähä-Koskela, Caroline Heckman, Jenni Lahtela, Ulla Wartiovaara-Kautto, Esa Pitkänen, Outi Kilpivaara
Publikováno v:
HemaSphere, Vol 7, p e8517818 (2023)
Externí odkaz:
https://doaj.org/article/708260efd88a41cea3e25e302d29c906
Autor:
Suvi P. M. Douglas, Atte K. Lahtinen, Jessica R. Koski, Lilli Leimi, Mikko A. I. Keränen, Minna Koskenvuo, Caroline A. Heckman, Kirsi Jahnukainen, Esa Pitkänen, Ulla Wartiovaara-Kautto, Outi Kilpivaara
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-9 (2022)
Abstract Despite recent progress in acute lymphoblastic leukemia (ALL) therapies, a significant subset of adult and pediatric ALL patients has a dismal prognosis. Better understanding of leukemogenesis and recognition of germline genetic changes may
Externí odkaz:
https://doaj.org/article/65565a374821414dab854c43e940b4e9
Autor:
Nicolas Boissel, Patrice Chevallier, Vadim Doronin, Laimonas Griskevicius, Alexey Maschan, James McCloskey, Alessandro Rambaldi, Giuseppe Rossi, Andrey Sokolov, Ulla Wartiovaara‐Kautto, Corina Oprea, Giovanni Abbadessa, Alice Gosselin, Sandrine Macé, Xavier Thomas
Publikováno v:
Cancer Medicine, Vol 11, Iss 5, Pp 1292-1298 (2022)
Abstract The poor prognosis of acute T‐cell lymphoblastic leukemia (T‐ALL) and T‐cell lymphoblastic lymphoma (T‐LBL) in older adults and patients with relapsed/refractory illness is an unmet clinical need, as there is no defined standard of c
Externí odkaz:
https://doaj.org/article/8eb438a3278541aab472cb141756c479
Autor:
Minja Pehrsson, Hanna Heikkinen, Ulla Wartiovaara-Kautto, Sampo Mäntylahti, Pia Bäckström, Mariann I. Lassenius, Kristiina Uusi-Rauva, Olli Carpén, Kaisa Elomaa
Publikováno v:
Molecular Genetics and Metabolism Reports, Vol 33, Iss , Pp 100911- (2022)
Background: Autosomal recessive Gaucher disease (GD) is likely underdiagnosed in many countries. Because the number of diagnosed GD patients in Finland is relatively low, and the true prevalence is currently not known, it was hypothesized that undiag
Externí odkaz:
https://doaj.org/article/b89df55e164e428891087e026837972c
Autor:
Hanna L. M. Rajala, Veli-Jukka Anttila, Mikko Haapio, Mikko A. I. Keränen, Ulla Wartiovaara-Kautto, Riikka Räty
Publikováno v:
Case Reports in Hematology, Vol 2021 (2021)
Gemtuzumab-ozogamicin (GO) is a humanized anti-CD33 antibody, which is conjugated to a cytotoxic calicheamicin. It is used to treat acute myeloid leukemia (AML) in combination with chemotherapy. We describe here two GO-treated acute myeloid leukemia
Externí odkaz:
https://doaj.org/article/3b672f54672f49918c8d96fb2cedac09
Autor:
Panagiotis Baliakas, Bianca Tesi, Ulla Wartiovaara-Kautto, Asbjørg Stray-Pedersen, Lone Smidstrup Friis, Ingunn Dybedal, Randi Hovland, Kirsi Jahnukainen, Klas Raaschou-Jensen, Per Ljungman, Cecilie F. Rustad, Charlotte K. Lautrup, Outi Kilpivaara, Astrid Olsnes Kittang, Kirsten Grønbæk, Jörg Cammenga, Eva Hellström-Lindberg, Mette K. Andersen
Publikováno v:
HemaSphere, Vol 3, Iss 6, p e321 (2019)
Abstract. Myeloid neoplasms (MNs) with germline predisposition have recently been recognized as novel entities in the latest World Health Organization (WHO) classification for MNs. Individuals with MNs due to germline predisposition exhibit increased
Externí odkaz:
https://doaj.org/article/e012695ca5da41d3893550e56ca30089
Autor:
Luca Trotta, Anna Norberg, Mervi Taskinen, Vivien Béziat, Sofie Degerman, Ulla Wartiovaara-Kautto, Hannamari Välimaa, Kirsi Jahnukainen, Jean-Laurent Casanova, Mikko Seppänen, Janna Saarela, Minna Koskenvuo, Timi Martelius
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 13, Iss 1, Pp 1-9 (2018)
Abstract Background The telomere biology disorders (TBDs) include a range of multisystem diseases characterized by mucocutaneous symptoms and bone marrow failure. In dyskeratosis congenita (DKC), the clinical features of TBDs stem from the depletion
Externí odkaz:
https://doaj.org/article/d877411b75874771a7bb8c318f40058e
Autor:
Atte K. Lahtinen, Jessica Koski, Jarmo Ritari, Kati Hyvärinen, Satu Koskela, Jukka Partanen, Kim Vettenranta, Minna Koskenvuo, Riitta Niittyvuopio, Urpu Salmenniemi, Maija Itälä-Remes, Kirsi Jahnukainen, Outi Kilpivaara, Ulla Wartiovaara-Kautto
Publikováno v:
Bone Marrow Transplantation. 58:39-45
Allogeneic hematopoietic stem cell transplantation (HSCT) provides patients with severe hematologic disease a well-established potential for curation. Incorporation of germline analyses in the workup of HSCT patients is not a common practice. Recogni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ef27f4096723a5a50ba40dfba241963
https://doi.org/10.1038/s41409-022-01828-x
https://doi.org/10.1038/s41409-022-01828-x